证券代码：688105 证券简称：诺唯赞 公告编号：2025-007 南京诺唯赞生物科技股份有限公司 关于变更注册资本 、修订《公司章程》 并完成工商变更登记换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于近日完成变更注 册资本、修订《公司章程》的工商登记手续，收到南京市市场监督管理局换发的 《营业执照》，现将相关内容公告如下： 一、关于变更公司注册资本的情况 公司分别于 2024 年 12 月 11 日、2024 年 12 月 30 日召开第二届董事会第十 四次会议、2024 年第一次临时股东大会，授权公司董事会办理注销回购股份、 变更公司注册资本及修订《公司章程》等相关事项，并根据相关法规的要求，就 本次注销回购股份事项履行债权人通知程序（公告编号：2024-066、074、075）。 2025 年 2 月 6 日，公司完成了上述回购股份的注销工作，公司总股本、注 册资本分别变更为 397,734,544 股、397,734,544 元，具体详见公 ...

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.96% on March 7, 2025, underperforming the CSI 300 Index by 0.65 percentage points, ranking 22nd among 31 sub-industries [4]. - The approval of ARS's Neffy (1 mg epinephrine nasal spray) by the FDA marks a significant innovation in the delivery method for treating type I allergic reactions in children aged 4 and above, representing the first major advancement in 35 years for this patient group [5][9]. - Notable stock performances included Aosaikang (+9.99%), Yipinhong (+9.77%), and Rejing Biology (+8.84%) on the gainers' list, while Aopumai (-6.26%), Puri Eye (-5.97%), and BGI (-4.86%) led the decliners [4]. Summary by Sections Market Performance - As of March 7, 2025, the pharmaceutical sector's performance was -0.96%, with sub-sectors like in vitro diagnostics (-0.43%) and blood products (-0.72%) performing better, while hospitals (-2.11%) and medical devices (-1.67%) lagged [4]. Industry News - The FDA's approval of Neffy is a pivotal development for the treatment of severe allergic reactions in children, highlighting the ongoing innovation in the pharmaceutical industry [5]. - Companies such as Jingxin Pharmaceutical announced an increase in their share repurchase plan, raising the total amount from a minimum of 200 million RMB to 350 million RMB [5]. - Nouvegen and BGI have entered a strategic cooperation agreement to leverage their respective expertise in reproductive genetics, tumor prevention, chronic disease management, and infection control [5]. Company News - Heng Rui Pharmaceutical received approval for clinical trials of several new drugs, indicating ongoing research and development efforts [6]. - Kanglong Chemical reported the completion of a share reduction plan, with a total of 10,666,716 shares reduced, representing 0.60% of the company's total share capital [6].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-006 南京诺唯赞生物科技股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司与华大基因近日于深圳市签署了《战略合作协议》，具体情况如下： 一、协议签订的基本情况 （一）协议对方基本情况 | 企业名称 | 深圳华大基因股份有限公司（300676.SZ） | | | | | --- | --- | --- | --- | --- | | 企业性质 | 其他股份有限公司（上市） | | | | | 法定代表人 | 赵立见 | | | | | 注册资本 | 41,582.1575 万元 | | | | | 成立日期 | 2010 月 日 | 年 | 7 | 9 | | 注册地址 | 深圳市盐田区洪安三街 21 号华大综合园 7 栋 7 层-14 层 | | | | | 经营范围 | 贸易经纪与代理。住房租赁；非居住房地产租赁。（除依法须经批准 | | | | | | 的项目外，凭营业执照依法自主开展经营 ...

Financial Performance - The company achieved total operating revenue of CNY 1,370,962,630.03, representing a year-on-year increase of 6.61%[3] - The net profit attributable to the parent company was CNY -17,001,790.83, a reduction in loss of CNY 5,395,440 compared to the previous year[4] - The total assets at the end of the reporting period were CNY 5,051,433,120.96, a decrease of 12.09% from the beginning of the period[4] - The equity attributable to the parent company was CNY 3,946,870,040.93, down 2.05% from the beginning of the period[3] - The company reported a basic earnings per share of CNY -0.04, an improvement from CNY -0.18 in the previous year[3] Business Strategy - The company focused on market demand and development opportunities, leading to rapid growth in new product lines and international business[4] - The company emphasized internal control measures to manage costs and reduce risks[4] Asset Management - The company effectively reduced asset impairment losses, which significantly decreased year-on-year[4] Government Subsidies - The company experienced a substantial reduction in government subsidy-related income during the reporting period[5] Financial Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[6]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-004 南京诺唯赞生物科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/6，由公司董事长兼总经理、实际控制人 曹林先生提议 | | --- | --- | | 回购方案实施期限 | 待公司董事会审议通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购价格上限 | 29.87 元/股 | | 回购用途 | √减少注册资本 □为维护公司价值及股东权益 | | 实际回购股数 | 4,399,299 股 | | 实际回购股数占总股本比例 | 1.09% | | 实际回购金额 | 10,600.41 万元 | | 实际回购价格区间 | 17.65 元/股~28.65 元/股 | 一、回购审批情况和回购方案内容 南京诺唯赞生物科技股份有限公司(以下简称"公司")于 2024 年 2 月 5 日召 开第二届董事会第八次会议，审 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 27.98 CNY [3][6]. Core Views - The company is experiencing rapid growth in overseas business and is optimistic about the volume of new products being launched [2]. - Revenue and profit forecasts have been adjusted downwards due to industry demand fluctuations, reduced income from COVID-19 products, and increased R&D investments [3]. - The company is expected to achieve earnings per share of -0.03 CNY in 2024, 0.27 CNY in 2025, and 0.45 CNY in 2026 [3]. Financial Performance Summary - The company's revenue for 2022 was 3,569 million CNY, with a projected decline to 1,286 million CNY in 2023, followed by a recovery to 1,467 million CNY in 2024, and further growth to 1,845 million CNY in 2025 and 2,287 million CNY in 2026 [5]. - The gross profit margin is expected to improve from 71.0% in 2023 to 77.3% by 2026 [5]. - The net profit attributable to the parent company is projected to recover from a loss of 71 million CNY in 2023 to a profit of 179 million CNY in 2026 [5]. Business Segment Insights - The life sciences segment is seeing stable growth with continuous upgrades and new product launches [7]. - The in vitro diagnostics segment has expanded its reach, covering over 2,800 hospitals with rapid growth in respiratory pathogen detection products [7]. - The biopharmaceutical segment has achieved significant production scale, becoming a major supplier of enzyme raw materials in China [7]. R&D and Cost Management - The company has maintained a strong commitment to R&D, with R&D expenses accounting for 21.8% of revenue in the first three quarters of 2024 [7]. - Effective cost control measures have led to a reduction in management and sales expense ratios [7].

Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between -20 million and -12 million RMB, a reduction in loss of 50.96 million to 58.96 million RMB compared to the same period last year, representing a year-on-year reduction in loss of 71.81% to 83.09%[2]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to be between -85 million and -77 million RMB, a reduction in loss of 107.73 million to 115.73 million RMB compared to the same period last year, representing a year-on-year reduction in loss of 55.90% to 60.05%[2]. - The total profit for the year 2023 was -115.71 million RMB, with a net profit attributable to shareholders of the parent company of -70.96 million RMB[3]. Operational Improvements - The company has implemented measures such as information system construction and business process optimization, leading to improved operational efficiency compared to the previous period[5]. - The company has seen a significant decrease in asset impairment losses compared to the previous period[5]. R&D Investment - R&D expenditure has decreased year-on-year, but the company maintains a relatively high R&D investment intensity, focusing on areas such as neurological detection and microfluidic product lines[5]. Revenue and Subsidies - Revenue related to government subsidies has significantly decreased during the reporting period[5]. Earnings Forecast and Risks - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast[6]. - The earnings forecast is based on preliminary internal calculations and has not been audited by a registered accountant[6]. - Investors are advised to pay attention to investment risks as the final audited annual report will provide more accurate information[6].

重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 55 | | --- | --- | | 普通股股东人数 | 55 | | 2、出席会议的股东所持有的表决权数量 | 262,924,125 | | 普通股股东所持有表决权数量 | 262,924,125 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 66.0918 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 66.0918 | 证券代码：688105 证券简称：诺唯赞 公告编号：2024-075 南京诺唯赞生物科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长曹林先生主持，会议采用现场投票 和网络投票相结 ...

北京市天元律师事务所 关于南京诺唯赞生物科技股份有限公司 2024 年第一次临时股东大会的 www.tylaw.com.cn 本次股东大会的召开，并参与了本次股东大会议案表决票的现场监票计票工作。 致：南京诺唯赞生物科技股份有限公司 南京诺唯赞生物科技股份有限公司（以下简称"公司"）2024 年第一次临时股 东大会（以下简称"本次股东大会"）采用现场投票与网络投票相结合的方式召开， 现场会议于 2024 年 12 月 30 日下午 15:00 在南京市栖霞区科创路红枫科技园 D2 栋公司 1 楼报告厅 召开 。北京市天元律师事务所（以下简称"本所"）接受公司聘 任，指派本所律师参加本次股东大会现场会议，并根据《中华人民共和国公司法》、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）以及《南京诺唯赞生物科技股份有限公司章程》 （以下简称"《公司章程》"）等有关规定，就本次股东大会的召集、召开程序、出 席现场会议人员的资格、召集人资格、会议表决程序和表决结果等有关事宜出具本 法律意见。 为出具本法律意见，本所律师审查了《南京诺唯赞生物科技股份有限公司 ...

南京诺唯赞生物科技股份有限公司 2024 年第一次临时股东大会 会议资料 2024 年 12 月 南京诺唯赞生物科技股份有限公司 2024 年第一次临时股东大会会议须知 为维护全体股东合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、中 国证券监督管理委员会《上市公司股东大会规则》以及《南京诺唯赞生物科技股 份有限公司章程》、《南京诺唯赞生物科技股份有限公司股东大会议事规则》等 有关规定，南京诺唯赞生物科技股份有限公司（以下简称"公司"）特制定本次 股东大会会议须知： 一、董事会在股东大会召开过程中，应当以维护股东的合法权益、确保正常 程序和议事效率为原则，认真履行法定职责。股东大会设立秘书处，负责大会有 关程序方面事宜。 二、各股东（含股东代理人，下同）请按照本次股东大会会议通知中规定的 时间和登记方法办理参会手续，详见公司刊登于上海证券交易所网站 （www.sse.com.cn）的《关于召开 2024 年第一次临时股东大会的通知》（公告 编号：2024-070），证明文件不齐或手续不全的，谢绝参会。为确认出席大会的 股东及其他出席者的 ...